CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more

Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’ experimental CAR-T therapy. Novartis has paused immunology and neuroscience ... Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and…

Source: Endpoints News